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the peripheral anastomosis increased in all of these at t3. 
Two eyes remained unchanged through the whole length of 
follow-up.  Conclusions: Significant changes in the CNV net 
can be observable in OCTA at least 1 week after intravitreal 
anti-VEGF. The safety of frequent examinations may provide 
a method of gauging treatment effects. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 Age-related macular degeneration (AMD) is the lead-
ing cause of irreversible, severe vision loss in developed 
countries among people aged  ≥ 55 years  [1] . In neovas-
cular AMD, the presence of abnormal blood vessels aris-
ing from the choroid – choroidal neovascularization 
(CNV) – can be found between Bruch’s membrane and the 
retinal pigmented epithelium (type 1) or in the subretinal 
space (type 2). The angiogenesis associated with the CNV 
lesions leads to bleeding, exudation and ultimately to the 
formation of a fibrovascular scar, resulting in severe pho-
toreceptor damage and vision loss  [2] . Early diagnosis is 
crucial for initiating and guiding treatment, which nowa-
days relies on repeated intravitreal injections of monoclo-
nal antibodies to the vascular endothelial growth factor 
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 Abstract 
 Purpose: To assess and describe sequential morphological 
changes in the choroidal neovascularization (CNV) net using 
optical coherence tomography angiography (OCTA) in pa-
tients undergoing treatment with intravitreal antivascular 
endothelial growth factor (VEGF).  Methods: Prospective co-
hort study. OCTA was performed sequentially: before (t0), 
1 h (t1), 1 week (t2) and 1 month after the injection (t3), using 
Avanti RTVue XR equipped with the AngioVue ® software 
(Optovue, Calif., USA). All images were classified by two in-
dependent graders.  Results: Ten eyes of 10 patients, with a 
mean age of 72.4 ± 10.5 years, were included. CNV morphol-
ogy was described as tree-like in 5 eyes, glomerular in 1 and 
fragmented in 4. A fibrovascular capsule surrounding the 
CNV net was found in 4 eyes and a feeder trunk was noticed 
in 6. No changes were observed at t1. Loss of peripheral cap-
illaries, vessel fragmentation and decreased vessel density 
were evident in 8 eyes at t2. The CNV capillary density and 
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(VEGF). Anti-VEGF drugs blunt the progression of the 
disease process by halting the germination of new vessels 
and decreasing VEGF-mediated vascular leakage, hence 
reducing the risk of progressive and enduring visual loss. 
Ancillary diagnostic tests like fluorescein angiography 
(FA), indocyanine green angiography (ICGA) and spectral 
domain optical coherence tomography (SD-OCT) have 
led to a better understanding of the pathophysiological 
features of several retinal diseases, including AMD  [3] . FA 
remains the gold standard for the diagnosis and classifica-
tion of AMD-related CNV, whereas ICGA is used to image 
subretinal pigmented epithelium components of the CNV, 
as it offers better visualization of the deep vessels due to 
excitation and resultant fluorescence in the near-infrared 
region  [4] . Both FA and ICGA are invasive imaging tech-
niques that require intravenous injection of a dye – fluo-
rescein or indocyanine green, respectively. Although gen-
erally safe, side effects like nausea, vomiting or even severe 
allergic reactions may develop in a minority of patients, 
thus limiting its repeated use  [5, 6] . The advent of OCT 
revolutionized retinal imaging by providing a fast, simple 
and noninvasive method to assess retinal structure at a mi-
croscopic level  [7, 8] . The high resolution of SD-OCT al-
lows visualization of some morphological features of the 
fibrovascular complex and the exudative consequences of 
fluid accumulation in the retina. However, even the most 
advanced structural OCTs do not provide an adequate vi-
sualization of the choriocapillaries.
 OCT angiography (OCTA) is a revolutionary imaging 
technique that allows noninvasive, 3-dimensional visual-
ization of the retinal and choroidal vasculature via mo-
tion contrast imaging  [9, 10] . OCTA detects endoluminal 
flow by mapping erythrocyte movement over time and 
comparing sequential OCT B scans at a given cross-sec-
tion  [9] . By using the en face OCT technology, layer seg-
mentation is automatically generated to identify areas of 
interest, such as the superficial and deep retinal vascular 
plexuses or the choriocapillaries  [11, 12] . In order to min-
imize unavoidable saccadic artifacts and the signal-to-
noise ratio of flow detection, amplitude-based algorithms, 
calculating differences in intensity between structures, 
were developed  [13, 14] . Motion correction is achieved by 
merging two orthogonally captured imaging volumes. 
The split-spectrum amplitude-decorrelation angiogra-
phy algorithm is a patented primary technology described 
by Jia et al.  [13] that improves both signal-to-noise ratio 
for flow detection and connectivity of microvascular net-
work, by splitting the spectrum of two original repeat 
OCT frames. The incorporation of these technologies in 
OCTA further enhanced the quality of the vascular im-
ages, thus enabling the in vivo  acquisition of high-speed, 
dyeless, microvascular angiograms, representing a true 
extension of capabilities from SD-OCT  [10, 15] .
 While still in a germinal stage, studies on the clinical 
applications of OCTA are beginning to materialize, 
namely in the field of exudative AMD  [4, 9, 10, 16–18] . 
OCTA has been shown to allow a noninvasive evaluation 
of the CNV net  [19–21] , with 50 and 91% reported sensi-
tivity and specificity for CNV detection, respectively  [9] . 
Its inherent advantages appear to be the ability to opti-
cally dissect and visualize flow in different layers of the 
retina, the high obtainable resolution and the freedom 
and safety of frequent examinations  [22] . Anecdotal case 
reports  [17, 20, 23] have shown that changes in the CNV 
net can be expected to occur after treatment with anti-
VEGF drugs. Quantitative measurements of the CNV 
flow area and flow index reported by Huang et al.  [20] 
showed a rapid shutdown of flow over the initial 2 weeks, 
followed by reappearance of the CNV channel by the 
fourth week and fluid reaccumulation at 6 weeks. In ac-
cordance with this, Lumbroso et al.  [19] described a pat-
tern of cyclic variation in the CNV net after each anti-
VEGF injection, starting as soon as 24 h after treatment. 
A comprehensive assessment of the CNV net changes 
that each patient undergoes during treatment may lead to 
better monitoring of treatment response and ultimately 
to the development of customized treatment regimens. 
Using a fixed schedule of OCTA examinations (before, 
1 h after, 1 week after and 1 month after intravitreal anti-
VEGF), this study was designed to (1) assess and describe 
sequential morphological changes in the CNV net in a 
cohort of exudative AMD patients undergoing treatment 
with intravitreal injections of anti-VEGF and (2) evaluate 
whether the reported changes in the CNV net can be seen 
as soon as 1 h after treatment.
 Methods 
 Prospective cohort study. The study followed the tenets of the 
Declaration of Helsinki for biomedical research and was approved 
by the local Ethics Committee. Informed consent was obtained for 
every included subject.
 Patients undergoing intravitreal injections of anti-VEGF com-
pounds for AMD-related CNV were included in the study. Eligibil-
ity criteria were: (1) either race or sex; (2) confirmed diagnosis of 
AMD-related CNV with ancillary multimodal retinal imaging, i.e. 
color fundus photography, FA, ICGA and SD-OCT; (3) ability to 
attend regular follow-up visits; (4) ability to maintain accurate tar-
get fixation, and (5) no significant media opacities likely to jeop-
ardize image acquisition or interpretation. Patients with a visual 
acuity of 20/100 or less and those with a signal strength of 55 or 
less were not included in this study.
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 Optical Coherence Tomography Angiography  
 OCTA was performed with the 70-kHz Avanti RTVue XR 
equipped with the AngioVue software (Optovue Inc., Fremont, 
Calif., USA), with a light source centered at 840 nm, a bandwidth 
of 45 nm, and an A scan rate of 70,000 scans/s. The macular angi-
ography scans covered a 3 × 3 mm area, each macular cube consist-
ing of 304 clusters of 2 repeated B scans containing 304 A scans 
each. Motion correction and the split-spectrum amplitude-decor-
relation angiography algorithm were employed to minimize un-
avoidable saccadic artifacts and improve the signal-to-noise ratio, 
respectively. OCTA was performed sequentially in the CNV group: 
before the intravitreal injection (t0), 1 h (t1), 1 week (t2) and 
1 month after the injection (t3). Automated segmentation was 
used to visualize neovascular tissue in the plane above Bruch’s 
membrane. However, when automated techniques failed, the area 
of segmentation was manually adjusted until the tissue of interest 
was visualized. The best images that showed neovascular tissue 
were chosen for analysis. 
 Image Analysis 
 All images were classified by two independent graders (J.P.M. 
and J.C.). For the certification process, the graders had to success-
fully identify the CNV net and its morphology in a set of 20 OCTA 
images of patients attending the AMD clinic of our center. In the 
baseline scans (t0), the CNV net morphology was categorized into 
tree-like, glomerular or fragmented, as previously described by 
Lumbroso et al.  [11] . The presence of a fibrovascular capsule and 
feeder trunk were assessed. In the sequential analysis of the OCTA 
scans, the status of the CNV net and surrounding choriocapillaris 
were thoroughly evaluated, specifically searching for loss of pe-
ripheral capillaries, vessel pruning or fragmentation and decreased 
vascular density. 
 Results 
 Demographic and clinical characteristics of the in-
cluded patients are shown in  table 1 . Ten eyes of 10 pa-
tients with neovascular AMD and a mean age of 72.4 ± 
10.5 years, were included in this study. All patients com-
pleted 1 month of follow-up and attended all the sched-
uled visits (t0, t1, t2 and t3). Three patients were treat-
ment naive, while all the others had already received at 
least 1 intravitreal injection of ranibizumab. The CNV net 
was discernible in the OCTA scan of every patient. Its lo-
cation was compared with color fundus photography, FA 
and ICGA. In all cases, OCTA provided a more distinc-
tive pattern of the vascular network, not obscured by leak-
age or subretinal hemorrhage ( fig. 1 c, d). The CNV net 
originated from regions of severe choriocapillaris altera-
tion. In the baseline scans (t0), the CNV morphology was 
described as tree-like in 5 eyes, glomerular in 1 and frag-
mented in 4 ( fig. 2 a, b, c). The presence of a fibrovascular 
capsule surrounding the CNV net was found in 4 eyes, 
and a central feeder trunk was noticed in 6 ( fig. 2 a, c, d). 
One hour (t1) after the intravitreal injection, no changes 
in the CNV net were observed in any of the included sub-
jects. Loss of peripheral capillaries, vessel pruning or frag-
mentation and decreased vessel density were evident in 
8 eyes at t2 (1 week after the injection), even though the 
central, larger vessels remained unchanged. The CNV 
capillary density and the peripheral anastomosis in-
creased in all of these cases from t2 to t3 ( fig. 1 f, g, h, i, 
 fig. 3 ). No discernible changes in the CNV net were found 
through the whole length of follow-up in 2 eyes (cases 2 
and 7). 
 Discussion 
 Previous studies have demonstrated that OCTA allows 
accurate imaging of AMD-related type 1 and type 2 CNV 
 [9, 10, 16, 18, 21] . Correspondingly, in this study the CNV 
net was detectable in the baseline OCTA scan of every in-
cluded patient, allowing a comprehensive visualization of 
the morphology and microvascular details of the CNV 
net, not obscured by leakage or subretinal hemorrhage. 
Furthermore, sequential changes after anti-VEGF treat-
ment were identified in 80% of our study population, 
which was in agreement with the notion that following 
treatment with anti-VEGF, the level of free VEGF drops 
precipitously, and newly growing vascular sprouts regress 
 [4] . Even though several authors have reported longitu-
dinal changes in the neovascular network after treatment, 
most of these are anecdotal case reports  [17, 20, 23] or 
small case series  [24] with varying OCTA evaluations 
over time. Albeit important, case reports have significant 
limitations, namely the fact that their observations can-
 Table 1.  Clinical and demographic data from the study population
Case Age,
years
Sex Eye Type of 
CNV
BCVA Number of previ-
ous injections
Current
anti-VEGF 
compound
1 89 F L Type 1 20/80 3 Ranibizumab Ranibizumab
2 79 F R Type 1 20/80 11 Ranibizumab Ranibizumab
3 60 F R Type 1 20/40 5 Ranibizumab Ranibizumab
4 70 F R Type 1 20/50 2 Ranibizumab Ranibizumab
5 67 M L Type 1 20/25 0 Aflibercept
6 56 F L Type 1 20/40 0 Ranibizumab
7 82 F L Type 1 20/80 18 Ranibizumab Ranibizumab
8 80 M R Type 2 20/80 3 Ranibizumab Ranibizumab
9 76 F R Type 1 20/60 1 Ranibizumab Ranibizumab
10 65 F L Type 2 20/30 0 Aflibercept
 BCVA = Best-corrected visual acuity; L = left; R = right.
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not be extrapolated to a clinical practice scenario. Se-
quential OCTA imaging in fixed intervals enables us to 
shadow the behavior of the CNV net after treatment, 
closely tracking the timings of vascular network remodel-
ing. This was demonstrated by Lumbroso et al.  [19] in a 
small cohort of 5 treatment-naive type 2 CNV patients. 
The authors reported changes in the CNV net starting as 
soon as 24 h after the injection and becoming progres-
sively more profuse up to 12–18 days after treatment. 
New vessel regrowth was noted 28–35 days after injec-
tion. In our study protocol we decided to evaluate wheth-
er these changes could be observable even earlier, i.e. 1 h 
after the intravitreal anti-VEGF injection. To our knowl-
edge this was the first study to use fixed OCTA imaging 
a b
c d e
f g h i
 Fig. 1. Multimodal retinal imaging of a 67-year-old treatment-na-
ive male (case 5).  a Infrared photography.  b A horizontal scan of 
enhanced-depth imaging SD-OCT at the corresponding black line 
in  a showing a type 1 parafoveal CNV lesion accompanied by sub-
retinal fluid and a subretinal hemorrhage.  c In the FA, visualization 
of the CNV net is obscured by leakage.  d An 8 × 8 mm OCTA scan 
shows a comprehensive glomerular-like CNV morphology, repre-
sented as a sketch in  e . Sequential 3 × 3 mm OCTA scans are de-
picted in the bottom set of images: before (t0;  f ) the intravitreal 
injection of aflibercept the glomerular-like CNV net with a central 
feeder trunk and peripheral anastomosis is clearly observed; 1 h 
after the injection (t1;  g ) there is no significant change in the CNV 
net; however, 1 week after the injection (t2;  h ) marked regression 
of the peripheral anastomosis and substantial capillary dropout 
can be seen, along with decreased new vessel density. The feeder 
trunk and some other central vessels are still visible.  i Note recan-
alization of the peripheral anastomosis, resumption of capillary 
sprouting and increased new vessel density 1 month after the in-
travitreal injection (t3). 
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intervals starting as soon as 1 h after treatment in a cohort 
of exudative AMD patients. Our results have shown that 
no significant changes can be found in the CNV net 1 h 
(t1) after the injection ( fig. 1 g,  3 b). However, 1 week after 
treatment (t2), peripheral new vessel pruning or frag-
mentation and decreased new vessel density were ob-
served ( fig. 1 h,  3 c), even though the central, larger vessels 
remained unchanged. The vulnerability of the branching 
peripheral capillaries is thought to occur due to the lack 
of pericytes shielding the vascular endothelial cells  [25] . 
On the other hand, the adequate pericyte coverage of the 
feeder trunk renders it resistant to anti-VEGF therapy 
a b
c d
 Fig. 2.  a A typical tree-like CNV morphol-
ogy with a central feeder trunk (white ar-
row) and branching ramifications (case 9). 
 b A fragmented CNV net morphology that 
did not change during the whole length of 
follow-up, in an 82-year-old female who 
had already undergone 18 ranibizumab in-
jections (case 7).  c A typical glomerular-
like pattern with a central feeder trunk 
(white arrow) and peripheral capillary 
sprouting (case 5).  d Note a fibrovascular 
capsule surrounding the CNV net (dashed 
line). 
a b c d
 Fig. 3. Sequential OCTA scans of a 60-year-old female with a his-
tory of 5 previous intravitreal injections of ranibizumab (case 3).
 a Baseline scan (t0) showing a tree-like CNV morphology.  b One 
hour (t1) after the intravitreal injection of ranibizumab, no appar-
ent changes in the CNV net could be observed.  c One week after 
the injection, there is modest capillary dropout (center of the 
dashed white circle) with regression of some peripheral anastomo-
sis.  d One month after the injection, central capillary density in-
creases, and the CNV net looks similar to the baseline scan. 
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alone, as the pericytes supply VEGF locally to their asso-
ciated vascular endothelial cells  [4] . Following the col-
lapse of the peripheral newly formed capillaries, the vas-
cular resistance for the entire vascular circuit rises, hence 
increasing the flow through the persisting vessels  [4] . This 
is a stimulus for arteriogenesis, a phenomenon that leads 
to dilation of preexisting vessels by active proliferation 
and remodeling of the vessel wall  [26] . Unlike angiogen-
esis (sprouting of new capillaries), arteriogenesis is not 
VEGF dependent. Spaide  [4] has recently highlighted that 
as the levels of anti-VEGF wane and unbound VEGF ris-
es, resumption of capillary sprouting inevitably follows. 
This was later demonstrated by Lumbroso et al.  [19] and 
was also observed in our study, where all cases that showed 
response to the anti-VEGF at t2 eventually increased cap-
illary density and the peripheral anastomosis from t2 to 
t3 ( fig. 1 i,  3 d). In the light of the current knowledge, the 
capillaries grow out of the formerly pruned larger branch-
es that expand in size due to arteriogenesis  [26] . Repeated 
anti-VEGF treatment trims back the newly growing ves-
sels and a vicious cycle ensues  [19] . Thus, the new vessel 
ingrowth caused by anti-VEGF compounds is nothing 
but periodic pruning of newly growing vessels (angiogen-
esis) in a setting of an unceasing stimulus for dilation (ar-
teriogenesis). Even though this approach is known to 
blunt the progression of the disease process by halting the 
sprouting of new capillaries and reducing VEGF-mediat-
ed vascular leakage, treating one feature of neovascular-
ization may not necessarily affect others  [4] . Albeit good, 
the current management of neovascular AMD is far from 
ideal and keeps the door open for emerging therapeutic 
options  [27] . Platelet-derived growth factor stimulates 
angiogenesis, as well as pericyte recruitment and matura-
tion  [28] . Therefore, inhibition of platelet-derived growth 
factor may increase endothelial cell sensitivity to anti-
VEGF agents. A phase III clinical trial with E10030 (Fo-
vista ® , Ophthotech Corporation, Princeton, N.J., USA), 
an anti-platelet-derived growth factor, is currently ongo-
ing to compare its efficacy when used concomitantly with 
ranibizumab versus ranibizumab monotherapy in sub-
jects with subfoveal CNV (NCT01940900).
 In 2 of our patients, no significant changes were found 
during the whole length of follow-up. Interestingly, these 
were the 2 cases with more previous intravitreal injec-
tions of anti-VEGF (11 and 18), which inevitably raises 
the question of tachyphylaxis. It would be interesting to 
appreciate whether a switch in the anti-VEGF agent 
would lead to any kind of vessel contraction in these set-
tings. Unfortunately this was not attempted in the current 
study.
 By determining the exact moment when the anti-
VEGF drug wanes in a certain patient we could poten-
tially tailor individual regimens instead of using fixed 
monthly injections. Measuring the aqueous or vitreous 
levels of VEGF are invasive and unfeasible procedures to 
use in clinical practice  [29–31] . With SD-OCT we can as-
sess the presence of subretinal fluid and pigment epithe-
lial detachments but we cannot accurately depict the 
CNV net. However, we may be able to use OCTA to pro-
vide customized treatment regimens depending on the 
CNV type and its response to intravitreal anti-VEGF, 
thus changing the current treatment regimens for exuda-
tive AMD. Future studies are needed to demonstrate this 
hypothesis.
 Limitations of this study include the restricted sample 
size, making it necessary to validate our findings and hy-
pothesis in further prospective reports involving a larger 
number of patients. Also, a quantitative analysis of the 
morphological changes was not performed in this study. 
Our results are purely descriptive, and a future evaluation 
of the clinical impact of its findings is warranted. The big-
gest strength of this study relies on its longitudinal design 
and reproducible methodology. 
 In conclusion, this study has shown that imaging the 
retinal and choroidal blood flow with OCTA allows for a 
comprehensive assessment of the CNV net morphology 
that far exceeds the information brought on by FA, ICGA 
and SD-OCT. The morphological changes that the CNV 
net undergoes in response to anti-VEGF are not visible 
1 h after the injection but can be clearly depicted 1 week 
after treatment. However, despite an initial positive re-
sponse, new vessel regrowth occurs from t2 to t3. Thus, 
the freedom and safety of frequent examinations with 
OCTA appear to provide a method of gauging treatment 
effects. Future implications of this may very well be the 
possibility of tailoring treatment regimens on an individ-
ual basis, hinging on the CNV net morphology at baseline 
and its response to a certain anti-VEGF compound.
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